{"id":"bisantrene","rwe":[],"tags":[{"label":"bisantrene","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"NAD(P)H dehydrogenase [quinone] 1","category":"target"},{"label":"NQO1","category":"gene"},{"label":"Active","category":"status"},{"label":"Antibiotics, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:38:02.664711","allNames":["bisantrene dihydrochloride","bisantrene hydrochloride","bisantrene"],"offLabel":[],"synonyms":["bisantrene dihydrochloride","bisantrene hydrochloride","bisantrene"],"timeline":[],"ecosystem":[],"mechanism":{"target":"NAD(P)H dehydrogenase [quinone] 1","targets":[{"gene":"NQO1","source":"DrugCentral","target":"NAD(P)H dehydrogenase [quinone] 1","protein":"NAD(P)H dehydrogenase [quinone] 1"}],"modality":"Small Molecule","drugClass":"bisantrene","explanation":"Think of it like a traffic cop: the enzyme is directing the flow of molecules to make cholesterol and other important compounds. Bisantrene is like a roadblock that stops this process, which can be helpful in treating certain conditions. However, this can also have unintended consequences, so it's essential to carefully consider the potential benefits and risks.","oneSentence":"Bisantrene works by blocking an enzyme called NAD(P)H dehydrogenase [quinone] 1, which is involved in the production of cholesterol and other steroids.","technicalDetail":"Bisantrene inhibits NAD(P)H dehydrogenase [quinone] 1, a flavoprotein enzyme involved in the reduction of quinones and the synthesis of cholesterol and other steroids through the mevalonate pathway."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/376","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BISANTRENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BISANTRENE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:00:17.805819","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:35.371597+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dicoumarol","drugSlug":"dicoumarol","fdaApproval":"1944-07-31","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"bisantrene","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(152)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dicoumarol","brandName":"dicoumarol","genericName":"dicoumarol","approvalYear":"1944","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04989335","phase":"PHASE2","title":"Bisantrene Combination for Resistant AML","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-08-02","conditions":["Myelogenous Leukemia, Acute"],"enrollment":29,"completionDate":"2025-12-01"},{"nctId":"NCT05456269","phase":"PHASE1","title":"A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS","status":"WITHDRAWN","sponsor":"Race Oncology Ltd","startDate":"2022-07-29","conditions":["Acute Myeloid Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","Higher Risk Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia"],"enrollment":0,"completionDate":"2023-08-31"},{"nctId":"NCT03820908","phase":"PHASE2","title":"Bisantrene for Relapsed /Refractory AML","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2019-07-18","conditions":["Acute Myelogenous Leukemia","Allogeneic Stem Cell Transplantation"],"enrollment":10,"completionDate":"2020-07-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"39C34M111K","CHEBI":"CHEBI:88337","INN_ID":"5131","UMLSCUI":"C0053776","ChEMBL_ID":"CHEMBL25336","DRUGBANK_ID":"DB17247","PUBCHEM_CID":"5351322","SECONDARY_CAS_RN":"71439-68-4","MESH_SUPPLEMENTAL_RECORD_UI":"C031404"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":152,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Sep 30","pmid":"41026253","title":"Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling.","journal":"Journal of clinical immunology"},{"date":"2025 Oct","pmid":"40746302","title":"Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.","journal":"British journal of haematology"},{"date":"2025 Mar 18","pmid":"40102495","title":"Anticancer drugs targeting topoisomerase II for antifungal treatment.","journal":"Scientific reports"},{"date":"2025 Jun","pmid":"40052926","title":"A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present.","journal":"Expert opinion on therapeutic patents"},{"date":"2023 Apr 27","pmid":"37071045","title":"Comment on \"Fluorimetric sensing of ATP in water by an imidazolium hydrazone based sensor\" by S. Farshbaf and P. Anzenbacher Jr., Chem. Commun., 2019, 55, 1770.","journal":"Chemical communications (Cambridge, England)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"BISANTRENE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bisantrene is a small molecule used in clinical trials for treating various conditions related to Acute Myelogenous Leukemia, including Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, and Refractory Acute Myeloid Leukemia. It has been studied in high and low doses of Bisantrene Dihydrochloride in clinical trials, with one completed trial focusing on its use for Relapsed/Refractory Acute Myelogenous Leukemia.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:41:35.371597+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}